BioCentury
ARTICLE | Clinical News

CBP501 regulatory update

January 16, 2012 8:00 AM UTC

FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects to complete a Phase II trial evaluating the product plus cispl...